|
|
|
(State or Other Jurisdiction
of Incorporation or Organization)
|
(Commission
File Number)
|
(I.R.S. Employer
Identification No.)
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
|
|
|
Item 8.01
|
Other Events.
|
Dated: November 7, 2022
|
Aquestive Therapeutics, Inc.
|
|
By:
|
/s/ A. Ernest Toth, Jr.
|
|
Name: A. Ernest Toth, Jr.
|
||
Title: Chief Financial Officer
|
Document and Entity Information |
Nov. 04, 2022 |
---|---|
Cover [Abstract] | |
Document Type | 8-K |
Amendment Flag | false |
Document Period End Date | Nov. 04, 2022 |
Entity File Number | 001-38599 |
Entity Registrant Name | Aquestive Therapeutics, Inc. |
Entity Central Index Key | 0001398733 |
Entity Incorporation, State or Country Code | DE |
Entity Tax Identification Number | 82-3827296 |
Entity Address, Address Line One | 30 Technology Drive |
Entity Address, City or Town | Warren |
Entity Address, State or Province | NJ |
Entity Address, Postal Zip Code | 07059 |
City Area Code | 908 |
Local Phone Number | 941-1900 |
Title of 12(b) Security | Common Stock, par value $0.001 per share |
Trading Symbol | AQST |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | true |
Entity Ex Transition Period | false |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
*K>
MK%_(0IA%G>=HD')>!07: